Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo.
To assess the vascular and cardiac response to NO (nitric oxide) synthase (NOS) blockade in vivo, Wistar-Kyoto rats (WKY) were treated for 3 wk with NG-nitro-L-arginine methyl ester (L-NAME; 10 mg.kg-1.day-1). L-NAME treatment induced hypertension that was associated with increased plasma renin activity. Flow cytometry cell cycle DNA analysis showed that aortic vascular smooth muscle cells (VSMC) from L-NAME-treated WKY had a significantly higher polyploid population compared with WKY controls. Using organ bath experiments, we have shown that aortic rings from L-NAME-treated WKY have an increased contractile response to phenylephrine and impaired relaxation to carbachol compared with control rings. NOS blockade in vivo caused a significant increase in cardiac and left ventricular hypertrophy. Northern mRNA analysis of the myocardium showed that L-NAME treatment caused reexpression of the fetal skeletal alpha-actin isoform without alterations in collagen type I expression, a pattern indicating true hypertrophy of the cardiomyocytes. These studies provide further insight to confirm that NO deficiency in vivo results in the development of vascular and cardiac hypertrophy.
Devlin
A M
AM
Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, United Kingdom.
Brosnan
M J
MJ
Graham
D
D
Morton
J J
JJ
McPhaden
A R
AR
McIntyre
M
M
Hamilton
C A
CA
Reid
J L
JL
Dominiczak
A F
AF
D000199:Actins / Q000096:biosynthesis; D000450:Aldosterone / Q000097:blood; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D002217:Carbachol / Q000494:pharmacology; D006332:Cardiomegaly / Q000139:chemically induced / Q000473:pathology*; D002453:Cell Cycle; D004247:DNA / Q000032:analysis; D006321:Heart / Q000187:drug effects; D006973:Hypertension / Q000139:chemically induced / Q000473:pathology* / Q000503:physiopathology; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects*; D018482:Muscle, Skeletal / Q000503:physiopathology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D009206:Myocardium / Q000166:cytology / Q000473:pathology*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D009599:Nitroprusside / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011123:Polyploidy; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D011921:Rats, Inbred WKY; D012084:Renin-Angiotensin System / Q000187:drug effects; D014158:Transcription, Genetic
D000199:Actins; D012333:RNA, Messenger; D009599:Nitroprusside; D010656:Phenylephrine; D000450:Aldosterone; D002217:Carbachol; D004247:DNA; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester